Andrew J Bett

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi request reprint Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans
    Andrew J Bett
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Vaccine 28:7881-9. 2010
  2. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
  3. pmc Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
    J Virol 78:11434-8. 2004
  4. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
  5. ncbi request reprint Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
    Rima Youil
    Merck and Company, West Point, PA 19486, USA
    Hum Gene Ther 14:1017-34. 2003
  6. ncbi request reprint Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines
    Miguel Aste-Amezaga
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Gene Ther 15:293-304. 2004
  7. doi request reprint Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques
    Daniel Distefano
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA, USA
    Vaccine 31:4888-93. 2013
  8. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
  9. pmc Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors
    Miguel Aste-Amezaga
    Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
    PLoS ONE 5:e9094. 2010
  10. ncbi request reprint Serotype specificity of adenovirus purification using anion-exchange chromatography
    John O Konz
    Biologics Development and Engineering, Merck Research Laboratories, West Point, PA 19486, USA
    Hum Gene Ther 16:1346-53. 2005

Collaborators

Detail Information

Publications11

  1. doi request reprint Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans
    Andrew J Bett
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Vaccine 28:7881-9. 2010
    ....
  2. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  3. pmc Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
    J Virol 78:11434-8. 2004
    ..The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity...
  4. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
    ..However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed...
  5. ncbi request reprint Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
    Rima Youil
    Merck and Company, West Point, PA 19486, USA
    Hum Gene Ther 14:1017-34. 2003
    ..This increased robustness will be critical when adapting first-generation recombinant adenovectors to commercial production...
  6. ncbi request reprint Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines
    Miguel Aste-Amezaga
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Gene Ther 15:293-304. 2004
    ..The evaluation of serotype-specific neutralizing antibodies can be of both clinical and epidemiologic importance as a means of selecting the appropriate serotype adenovector(s)...
  7. doi request reprint Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques
    Daniel Distefano
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA, USA
    Vaccine 31:4888-93. 2013
    ..Adjuvantation of whole-killed rabies vaccine for intramuscular injection may therefore be a viable alternative to intradermal application of non-adjuvanted vaccine for both pre- and post-exposure regimens...
  8. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  9. pmc Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors
    Miguel Aste-Amezaga
    Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
    PLoS ONE 5:e9094. 2010
    ..On the other hand, dysregulation of Notch1 signaling is associated with many different types of cancer as well as tumor angiogenesis, making Notch1 a potential therapeutic target...
  10. ncbi request reprint Serotype specificity of adenovirus purification using anion-exchange chromatography
    John O Konz
    Biologics Development and Engineering, Merck Research Laboratories, West Point, PA 19486, USA
    Hum Gene Ther 16:1346-53. 2005
    ..This correlation enables preparative chromatography gradients for alternative serotypes to be established with minimal effort...
  11. ncbi request reprint Hexon gene switch strategy for the generation of chimeric recombinant adenovirus
    Rima Youil
    Virus and Cell Biology, Merck and Co, Inc, West Point, PA, 19486, USA
    Hum Gene Ther 13:311-20. 2002
    ..The Ad5/Ad12 chimera was found to be extremely ineffective in the i.m. delivery and expression of HIV-1 gag in mice compared to the Ad5/Ad6 construct. Implications of these results will be discussed...